- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04696614
Testing the Effect of Exercise Intervention Using a SMART Design.
6. april 2022 oppdatert av: Yu-Hsuan Chang, National Taiwan University
Developing and Testing the Effect of Exercise Intervention Using a SMART Design on Reducing Visceral Adipose Tissue in Community Residents: A Mixed-Method, Longitudinal Study.
Exercise is the most effective way on reducing visceral adipose tissue (VAT), which is strongly linked with obesity to hypertension, cardiovascular disease, and insulin resistance.
However, the current exercise dosage for reducing VAT cannot be accurately quantified.
The aims of this study are to develop and test the optimal exercise dosage and sequence for reducing VAT in overweight and obese community residents.
Purposive sampling will be used to enroll at least 206 participants aged 40-65 years and body fat more than 30% without diet control from 2 community centers in southern Taiwan.
The project will use the sequential multiple assignment randomized trial (SMART) design to conduct a 16-week 2-stage (each for 8-weeks) adaptive exercise intervention for community residents.
In the first stage, participants will be randomized into groups performing 8 weeks either moderate intensity of aerobic exercise or interval training 3 times per week.
Participants whose VAT does not decrease by over 3%, measured using a body composition analyzer, compared with the baseline will be 1:1 rerandomized into groups with aerobic exercise combined with resistance exercise or received the exchange of first stage treatment (interval training or aerobic exercise) in the second stage.
Those with substantial response to the first-stage intervention (VAT reduction of more than 3%) will continue to receive the same exercise treatment until 16 weeks.
Linear mixed model, weighted and replicated regression will be used to identify the optimal sequence of exercises for the greatest reduction in VAT.
The findings can assist clinical health workers to develop exercise prescriptions for effectively reducing VAT, and help community residents reduce VAT through exercise to achieve the health promotion.
Studieoversikt
Studietype
Intervensjonell
Registrering (Faktiske)
116
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Tainan, Taiwan
- Community center
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
40 år til 64 år (Voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Community residents (a) who are 40-65 years old without diet control, (b) body fat ≧ 30% measured by body composition analyzer, and (c) can communicate in Mandarin or Taiwanese will be included.
Exclusion Criteria:
- This study will exclude residents with (a) recent unstable condition involving stroke or those with heart disease, handicap, pregnancy, mental disorders, systolic BP > 200 mmHg, or diastolic BP >110 mmHg; and (b) those with contraindications in body composition analyzer measurement including people with pacemakers, artificial metal joints, amputated hands or feet, and those who cannot be cooperated with standing during testing.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: aerobic exercise to aerobic exercise
first 8-week: aerobic exercise second 8-week: aerobic exercise
|
intervention groups provided different sequential modality of exercise
|
|
Eksperimentell: aerobic exercise to interval training
first 8-week: aerobic exercise second 8-week: interval training
|
intervention groups provided different sequential modality of exercise
|
|
Eksperimentell: aerobic exercise to aerobic exercise +resistance exercise
first 8-week: aerobic exercise second 8-week: aerobic exercise +resistance exercise
|
intervention groups provided different sequential modality of exercise
|
|
Eksperimentell: interval training to interval training
first 8-week: interval training second 8-week: interval training
|
intervention groups provided different sequential modality of exercise
|
|
Eksperimentell: interval training to aerobic exercise
first 8-week: interval training second 8-week: aerobic exercise
|
intervention groups provided different sequential modality of exercise
|
|
Eksperimentell: interval training to aerobic exercise+resistance exercise
first 8-week: interval training second 8-week: aerobic exercise +resistance exercise
|
intervention groups provided different sequential modality of exercise
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
visceral adipose tissue
Tidsramme: three times (baseline, change visceral adipose tissue from Baseline to 8 week, change visceral adipose tissue from Baseline to 16 week)
|
measured using body composition analyzer
|
three times (baseline, change visceral adipose tissue from Baseline to 8 week, change visceral adipose tissue from Baseline to 16 week)
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
10. november 2020
Primær fullføring (Faktiske)
4. januar 2021
Studiet fullført (Faktiske)
31. juli 2021
Datoer for studieregistrering
Først innsendt
4. januar 2021
Først innsendt som oppfylte QC-kriteriene
5. januar 2021
Først lagt ut (Faktiske)
6. januar 2021
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
7. april 2022
Siste oppdatering sendt inn som oppfylte QC-kriteriene
6. april 2022
Sist bekreftet
1. april 2022
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 108466
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .